Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biotime In-licenses Five Adlai Nortye Candidates in $32 Million Deal

publication date: Jan 26, 2022

Xiamen Biotime Biotech in-licensed a package of five drug assets (mostly preclinical) from Adlai Nortye, a Hangzhou oncology company, in an agreement worth at least $32 million. Adlai Nortye has built a pipeline of 10 candidates. Biotime, known for its point-of-care diagnostic devices, has recently branched out into drug development. It will have China rights including manufacturing for two of the candidates and global rights to the remaining three molecules. The China-only candidates are an oral small-molecule PD-L1 inhibitor and a novel humanized IgG1 (variant) anti-hTNFR2 antibody. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital